10x Genomics Q1 Results Beat Expectations but Shares Drop
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 43 minutes ago
0mins
Should l Buy TXG?
Source: Yahoo Finance
- Earnings Beat: 10x Genomics reported Q1 revenue of $150.8 million, a 2.6% year-over-year decline that, while exceeding Wall Street expectations, failed to boost investor sentiment, highlighting concerns about future growth prospects.
- Stock Volatility: The company's shares fell 5.3% in the afternoon session, closing at $21.61, down 3.6% from the previous close, reflecting investor caution regarding the company's growth potential in the near term.
- Market Reaction: With over 54 moves greater than 5% in the past year, today's decline indicates that the market considers this news significant, yet it does not fundamentally alter perceptions of the business.
- Long-term Investment Returns: Despite a 29.9% increase year-to-date, the stock is still trading 17.2% below its 52-week high, indicating poor returns for long-term investors, as those who invested $1,000 five years ago would now see only $160.12.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TXG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TXG
Wall Street analysts forecast TXG stock price to fall
10 Analyst Rating
4 Buy
6 Hold
0 Sell
Moderate Buy
Current: 20.500
Low
9.00
Averages
13.00
High
18.00
Current: 20.500
Low
9.00
Averages
13.00
High
18.00
About TXG
10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
10x Genomics Q1 Results Beat Expectations but Shares Drop
- Earnings Beat: 10x Genomics reported Q1 revenue of $150.8 million, a 2.6% year-over-year decline that, while exceeding Wall Street expectations, failed to boost investor sentiment, highlighting concerns about future growth prospects.
- Stock Volatility: The company's shares fell 5.3% in the afternoon session, closing at $21.61, down 3.6% from the previous close, reflecting investor caution regarding the company's growth potential in the near term.
- Market Reaction: With over 54 moves greater than 5% in the past year, today's decline indicates that the market considers this news significant, yet it does not fundamentally alter perceptions of the business.
- Long-term Investment Returns: Despite a 29.9% increase year-to-date, the stock is still trading 17.2% below its 52-week high, indicating poor returns for long-term investors, as those who invested $1,000 five years ago would now see only $160.12.
See More
Quantedge Capital Increases Stake in 10x Genomics
- Stake Increase: On May 12, 2026, Quantedge Capital disclosed in an SEC filing that it purchased 212,600 shares of 10x Genomics, valued at approximately $4.25 million, indicating confidence in the company's growth prospects.
- Value Growth: The recent stake increase resulted in a $5.52 million rise in the value of 10x Genomics' position at quarter-end, reflecting both the addition of shares and market price changes, thereby boosting investor confidence in its market performance.
- Financial Performance: Although 10x Genomics reported a 3% year-over-year decline in first-quarter revenue to $150.8 million, excluding one-time litigation revenue, actual sales grew by 9%, demonstrating strong market demand for its products.
- Product Innovation: The recent launch of the Atera platform, described as the most significant product introduction in the company's history, aims to advance spatial whole-transcriptome analysis, potentially laying the groundwork for AI-driven biological modeling and precision medicine.
See More
Torex Gold Resources Sees Major Earnings Upgrade
- Revenue Forecast Upgrade: The analyst raised Torex Gold Resources' 2026 revenue forecast from $2.0 billion to $2.3 billion, anticipating a significant 35% annual growth rate, which is a stark improvement over the historical 9.7% growth rate, indicating a strong enhancement in business fundamentals and future growth potential.
- Earnings Per Share Surge: Expected earnings per share are projected to rise from $6.48 to $7.86, marking a 28% increase, which not only reflects improved profitability but also has the potential to attract more investor interest, thereby driving the stock price higher.
- Positive Market Sentiment: Over the past week, Torex Gold's stock has surged 17% to CA$65.29, showcasing investor confidence in the company's growth prospects, and the analyst's upgrade may further propel the stock price, enhancing market recognition.
- Competitive Industry Position: Torex Gold's projected growth rate significantly outpaces the 17% annual growth forecast for other companies in the same industry, highlighting its competitive advantage; the analyst's optimistic outlook may draw more investor attention, bolstering its market position.
See More
10x Genomics Launches Atera Platform for Spatial Biology
- Platform Innovation: 10x Genomics has launched the Atera platform, which enables whole-transcriptome spatial analysis with single-cell sensitivity, marking a fundamental shift in biological analysis that is expected to advance medical research.
- Wide Applications: Atera supports spatial studies on both fresh-frozen and FFPE tissues, catering to diverse needs in discovery and translational research, helping institutions gain deeper insights into tumor microenvironments.
- High-Throughput Demand: Leading life sciences organizations have committed to utilizing Atera at scale, reflecting strong demand for high-throughput and high-sensitivity spatial analysis, driving progress in biopharma and translational research.
- Data Analysis Platform: 10x has also introduced a new cloud analysis platform to securely store and analyze spatial datasets, combining GPU-accelerated analysis to significantly enhance biologists' efficiency in deriving insights from raw data.
See More
10x Genomics Launches Atera Platform to Advance Spatial Biology
- Platform Innovation: 10x Genomics has launched the Atera platform, which enables whole-transcriptome spatial analysis with single-cell sensitivity, marking a fundamental shift in biological analysis that is expected to advance medical research significantly.
- Wide Applications: Atera supports large-scale spatial studies across both fresh-frozen and FFPE tissues, catering to diverse needs in discovery and translational research, thereby enhancing the depth and breadth of scientific inquiry.
- Clinical Data Showcase: Data from the June Lab at the University of Pennsylvania presented at the AACR 2026 highlighted Atera's application in tumor microenvironment studies, revealing the complexities of tumor dynamics post-CAR T cell therapy.
- Strong Market Demand: Leading life sciences organizations and research institutions have committed to utilizing Atera at scale, reflecting a robust demand for high-throughput, high-sensitivity spatial analysis that drives advancements in biopharma and translational research.
See More
Risks and Opportunities in Small-Cap Stocks
- Stratasys Performance Decline: Stratasys, with a market cap of $714.4 million, has experienced a 6.3% annual sales decline over the past two years, facing significant end-market challenges that raise doubts about its long-term business viability due to ongoing operating margin losses.
- 10x Genomics Growth Struggles: 10x Genomics, valued at $2.94 billion, reported only 1.9% annual revenue growth in the last two years, failing to meet healthcare sector standards, and its smaller revenue base has hindered its ability to achieve economies of scale, resulting in negative returns on capital.
- Atlas Energy Solutions Financial Pressure: Atlas Energy Solutions, with a market cap of $1.41 billion, has seen expenses increase as a percentage of revenue over the past five years, with its EBITDA margin falling by 20.8 percentage points, raising concerns about its ability to achieve sustainable long-term growth due to cash burn.
- Small-Cap Investment Risks: While small-cap stocks offer savvy investors the chance to act before broader market recognition, they also carry increased downside risks due to limited Wall Street coverage and lack of scale compared to larger competitors, necessitating careful selection by investors.
See More
10x Genomics Q1 Results Beat Expectations but Shares Drop
- Earnings Beat: 10x Genomics reported Q1 revenue of $150.8 million, a 2.6% year-over-year decline that, while exceeding Wall Street expectations, failed to boost investor sentiment, highlighting concerns about future growth prospects.
- Stock Volatility: The company's shares fell 5.3% in the afternoon session, closing at $21.61, down 3.6% from the previous close, reflecting investor caution regarding the company's growth potential in the near term.
- Market Reaction: With over 54 moves greater than 5% in the past year, today's decline indicates that the market considers this news significant, yet it does not fundamentally alter perceptions of the business.
- Long-term Investment Returns: Despite a 29.9% increase year-to-date, the stock is still trading 17.2% below its 52-week high, indicating poor returns for long-term investors, as those who invested $1,000 five years ago would now see only $160.12.
See More
Quantedge Capital Increases Stake in 10x Genomics
- Stake Increase: On May 12, 2026, Quantedge Capital disclosed in an SEC filing that it purchased 212,600 shares of 10x Genomics, valued at approximately $4.25 million, indicating confidence in the company's growth prospects.
- Value Growth: The recent stake increase resulted in a $5.52 million rise in the value of 10x Genomics' position at quarter-end, reflecting both the addition of shares and market price changes, thereby boosting investor confidence in its market performance.
- Financial Performance: Although 10x Genomics reported a 3% year-over-year decline in first-quarter revenue to $150.8 million, excluding one-time litigation revenue, actual sales grew by 9%, demonstrating strong market demand for its products.
- Product Innovation: The recent launch of the Atera platform, described as the most significant product introduction in the company's history, aims to advance spatial whole-transcriptome analysis, potentially laying the groundwork for AI-driven biological modeling and precision medicine.
See More
Torex Gold Resources Sees Major Earnings Upgrade
- Revenue Forecast Upgrade: The analyst raised Torex Gold Resources' 2026 revenue forecast from $2.0 billion to $2.3 billion, anticipating a significant 35% annual growth rate, which is a stark improvement over the historical 9.7% growth rate, indicating a strong enhancement in business fundamentals and future growth potential.
- Earnings Per Share Surge: Expected earnings per share are projected to rise from $6.48 to $7.86, marking a 28% increase, which not only reflects improved profitability but also has the potential to attract more investor interest, thereby driving the stock price higher.
- Positive Market Sentiment: Over the past week, Torex Gold's stock has surged 17% to CA$65.29, showcasing investor confidence in the company's growth prospects, and the analyst's upgrade may further propel the stock price, enhancing market recognition.
- Competitive Industry Position: Torex Gold's projected growth rate significantly outpaces the 17% annual growth forecast for other companies in the same industry, highlighting its competitive advantage; the analyst's optimistic outlook may draw more investor attention, bolstering its market position.
See More
10x Genomics Launches Atera Platform for Spatial Biology
- Platform Innovation: 10x Genomics has launched the Atera platform, which enables whole-transcriptome spatial analysis with single-cell sensitivity, marking a fundamental shift in biological analysis that is expected to advance medical research.
- Wide Applications: Atera supports spatial studies on both fresh-frozen and FFPE tissues, catering to diverse needs in discovery and translational research, helping institutions gain deeper insights into tumor microenvironments.
- High-Throughput Demand: Leading life sciences organizations have committed to utilizing Atera at scale, reflecting strong demand for high-throughput and high-sensitivity spatial analysis, driving progress in biopharma and translational research.
- Data Analysis Platform: 10x has also introduced a new cloud analysis platform to securely store and analyze spatial datasets, combining GPU-accelerated analysis to significantly enhance biologists' efficiency in deriving insights from raw data.
See More
10x Genomics Launches Atera Platform to Advance Spatial Biology
- Platform Innovation: 10x Genomics has launched the Atera platform, which enables whole-transcriptome spatial analysis with single-cell sensitivity, marking a fundamental shift in biological analysis that is expected to advance medical research significantly.
- Wide Applications: Atera supports large-scale spatial studies across both fresh-frozen and FFPE tissues, catering to diverse needs in discovery and translational research, thereby enhancing the depth and breadth of scientific inquiry.
- Clinical Data Showcase: Data from the June Lab at the University of Pennsylvania presented at the AACR 2026 highlighted Atera's application in tumor microenvironment studies, revealing the complexities of tumor dynamics post-CAR T cell therapy.
- Strong Market Demand: Leading life sciences organizations and research institutions have committed to utilizing Atera at scale, reflecting a robust demand for high-throughput, high-sensitivity spatial analysis that drives advancements in biopharma and translational research.
See More
Risks and Opportunities in Small-Cap Stocks
- Stratasys Performance Decline: Stratasys, with a market cap of $714.4 million, has experienced a 6.3% annual sales decline over the past two years, facing significant end-market challenges that raise doubts about its long-term business viability due to ongoing operating margin losses.
- 10x Genomics Growth Struggles: 10x Genomics, valued at $2.94 billion, reported only 1.9% annual revenue growth in the last two years, failing to meet healthcare sector standards, and its smaller revenue base has hindered its ability to achieve economies of scale, resulting in negative returns on capital.
- Atlas Energy Solutions Financial Pressure: Atlas Energy Solutions, with a market cap of $1.41 billion, has seen expenses increase as a percentage of revenue over the past five years, with its EBITDA margin falling by 20.8 percentage points, raising concerns about its ability to achieve sustainable long-term growth due to cash burn.
- Small-Cap Investment Risks: While small-cap stocks offer savvy investors the chance to act before broader market recognition, they also carry increased downside risks due to limited Wall Street coverage and lack of scale compared to larger competitors, necessitating careful selection by investors.
See More
